Atossa Therapeutics Inc (NASDAQ:ATOS)

1.57
Delayed Data
As of Oct 28
 -0.03 / -1.88%
Today’s Change
0.76
Today|||52-Week Range
5.08
0.00%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Medical Specialties
MARKET CAP
$19.0M

Company Description

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

Contact Information

Atossa Therapeutics, Inc.
107 Spring Street
Seattle Washington 98104
P:(206) 588-0256
Investor Relations:

Employees

Shareholders

Mutual fund holders2.76%
Other institutional0.10%
Individual stakeholders0.04%

Top Executives

Steven C. QuayChairman, President & Chief Executive Officer
Kyle GuseCFO, Secretary & Chief Accounting Officer
Devon PayneDirector-Clinical Operations
Bernadine Heather FraserVP-Clinical, Regulatory & CMC Division
Natalie FarrisSenior Director-CMC Division